Navigation Links
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
Date:7/27/2009

SOUTH PLAINFIELD, N.J., July 27 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors. PTC299 is a novel, orally administered investigational new drug that is designed to selectively block tumor-related vascular endothelial growth factor (VEGF). With its novel mechanism of action, PTC299 has the potential to meet significant unmet medical need in NF2 and other conditions resulting from the overexpression of VEGF.

(Logo:http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

VEGF plays a critical role in the formation of new blood vessels or angiogenesis and its suppression has been shown to decrease tumor size and improve hearing in some patients with NF2. PTC299 selectively blocks the tumor-related production of VEGF, while sparing the physiological VEGF expression necessary to maintain the growth and function of normal blood vessels. Patients with NF2 typically develop tumors that compress the auditory nerves, often leading to deafness and problems with balance. If unchecked, NF2-related tumors may eventually damage other cranial nerves and the brainstem, and become life-threatening. Current standard treatments for NF2-related tumors include surgery and radiation therapy. However, a study conducted at Massachusetts General Hospital and recently published in the New England Journal of Medicine validates the potential of anti-angiogenesis therapies for NF2 patients.

"The development of PTC299 for the treatment of NF2 is noteworthy for patients, especially following our recent findings that an angiogenesis inhibitor improved hearing and led to tumor shrinkage in some patients," said Sco
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
2. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
3. Cell Therapeutics, Inc. Announces Exercise of Overallotment
4. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
5. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
6. Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics
7. Tobira Therapeutics Inc. Announces Phase I Data Demonstrating Pharmacokinetic Properties of TAK-652 for the Treatment of HIV
8. Hygeia Therapeutics Signs an Exclusive License with Yale University for Potent, Safe Topical Anti-Androgens
9. Nile Therapeutics, Inc. Completes $3.4 Million Private Placement
10. Oxygen Biotherapeutics, Inc. Announces Closing of Private Placement Financing Agreement
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... According to a new market research report ... and Joint) Market (By Technology - Stem Cell ... Bone Graft Substitutes, Osteoarticular Diseases, Allogeneic Products, Autogenic ... Share, Growth, Trends and Forecast, 2013 - 2019" ... was valued at USD 2.6 billion in 2012 ...
(Date:7/28/2014)... YORK , July 28, 2014  David ... ConvergeHEALTH by Deloitte , has been elected ... Interchange Standards Consortium, a non-profit working to establish ... data, particularly as it relates to electronic health ... continue CDISC,s mission of collaborating with organizations across ...
(Date:7/28/2014)... 2014 The global market for biotechnology ... according to a new study by Grand View Research, ... for effective vaccines and drugs in an attempt to ... is expected to drive market demand over the next ... productivity via the use of genetically engineered seeds is ...
(Date:7/26/2014)... July 26, 2014 Canada Endoscopy ... market data on the Canada Endoscopy Visualization Systems ... US dollars, volume (in units) and average prices ... Endoscopy Visualization Systems, Mid-Range Endoscopy Visualization Systems and ... at http://www.marketresearchreports.biz/analysis/213254 . , The report also ...
Breaking Biology Technology:Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5
... researchers have identified a gene that is specifically responsible ... lead to stem cell therapies to treat brain injuries ... Edwin Monuki, doctoral student Karla Hirokawa and their colleagues ... Developmental & Cell Biology found that a gene called ...
... Jan. 17 NEXCORE Technology,Inc, a world-class original ... the intellectual property rights for the,development of a ... new system provides significantly greater control over the,inflow/outflow ... on the system are held by Drs. Atul ...
... Program Under Development to Improve Outcomes of Coronary ... Grafting (CABG) and Cardiac Valve Surgeries, VANCOUVER, ... -,Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI , TSX: ... that they have entered into an,exclusive licensing agreement ...
Cached Biology Technology:Discovery of 'creator' gene for cerebral cortex points to potential stem cell treatments 2NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System 2Angiotech and Symphony Medical Announce Licensing Agreement 2Angiotech and Symphony Medical Announce Licensing Agreement 3Angiotech and Symphony Medical Announce Licensing Agreement 4Angiotech and Symphony Medical Announce Licensing Agreement 5Angiotech and Symphony Medical Announce Licensing Agreement 6
(Date:7/28/2014)... suggest two ways to effectively address the problem that birth ... compared to women of a normal body mass index. , ... as the population has increased in weight, concern has grown ... have consistently found that obesity has a negative impact on ... how well the pill prevents pregnancy. , "Birth ...
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are ... of varying flexibility that can be used as microscale ... proof that "bead-spring" polymers, introduced as theory in the ... as required and should be of interest to materials ... The work led by Rice chemical and biomolecular engineer ...
(Date:7/28/2014)... body,s natural virus killers to prevent and treat HIV ... strong inflammatory response these molecules can arouse as they ... by scientists at the Weizmann Institute and the National ... activity of these molecules interferons around the ... course of the disease. Their research appeared in ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Seeing is bead-lieving 2Interfering with interferon 2
... syndrome has focused on the DYRK1A gene. The superexpression ... to Mr Garikoitz Azkona. In his PhD thesis, ... role of DYRK1A , Mr Azkona argues that this ... that persons with Down,s syndrome have regarding visual-spatial memory. ...
... 2010 2009 estimates projected that in the United States ... and 14,600 women would die of the disease. Often ... and a relatively low 5-year survival rate of about 45%. ... in the March 2010 issue of the Journal of ...
... treatment for cancer might come from fish says a new ... the FASEB Journal ( http://www.fasebj.org ). In the ... or "DHA," and its derivatives in the body kill neuroblastoma ... a wide range of cancers, including neuroblastoma, medulloblastoma, colon, breast, ...
Cached Biology News:DYRK1A gene may be 1 of most influential factors in Down syndrome 2Dietary factors influence ovarian cancer survival rates 2
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
AC input: 230 V...
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
Biology Products: